Comparing the current results to its competitors, Guardant Health Inc reported Revenue increase in the 2 quarter 2026 by 44.33 % year on year. The sales growth was above Guardant Health Inc 's competitors' average revenue growth of 11.29 %, achieved in the same quarter.
Guardant Health Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 79.57 %
Strong sales growth of 44.33 % in Overall company contributed to Guardant Health Inc increase in total revenue by 44.33 % Guardant Health Inc improved its market share in this segment, to approximately 1.81 %.
December 5, 2025
Guardant Health Showcases Innovative Liquid Biopsy Research at SABCS Amid Strong Revenue Growth Guardant Health, Inc. (NASDAQ: GH), a prominent player in the precision oncology landscape, is set to present 14 abstracts at the upcoming 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9-12, 2025. This presentation will highlight the contributions of its multiomic liquid biopsy tests, particularly the Guardant Reveal, which is designed to detect minimal residual disease (MRD) in both early and metastatic breast cancer. The studies, in collaboration with various research partners, aim to underscore the effectiveness of these tissue-free tests in personalizing treatment and improving patie...
April 30, 2025
In the race against cancer, Guardant Health, Inc. (Nasdaq: GH) is setting the pace with groundbreaking developments in multi-cancer detection technologies. At the recent 2025 American Association for Cancer Research (AACR) annual meeting, the leading precision oncology company unveiled compelling data showcasing the performance of its Shield multi-cancer detection (MCD) test across ten tumor types. This test demonstrates not only high specificity but also clinically meaningful sensitivity, marking a significant step forward in oncology diagnostics.The study results revealed that the Shield MCD test can effectively identify multiple cancers early on, offering critical insights that can guide clinical diagnost...
March 5, 2025
In a significant move to enhance cancer screening rates and advance precision oncology research, Guardant Health, a recognized leader in precision oncology, has announced partnerships with several organizations aimed at addressing critical public health challenges. The latest collaboration involves the Faith Fight Finish Foundation, initiated by Dallas Cowboys quarterback Dak Prescott, and the mobile cancer screening program, Partners in Wellness. The initiative, in partnership with LSU Health Shreveport and Ochsner LSU Health Feist-Weiller Cancer Center, is specifically targeted at increasing colorectal cancer screening in underserved communities across northern and central Louisiana. Colorectal cancer is c...
December 19, 2024
In the dynamic world of oncology, where the complexity of cancer demands innovative solutions, the partnership between COTA Inc. and Guardant Health Inc. represents a monumental shift towards a new frontier in precision oncology. This collaboration amalgamates the robust real-world clinicogenomic data and AI-driven analytics expertise of these two leading organizations, paving the way for transformative cancer therapies. Amid the backdrop of traditional barriers in oncology research, the partnership stands as a beacon of hope, shedding light on how technology and data can significantly accelerate the journey from research to treatment. Revolutionizing Precision Oncology with Real-World Data COTA Inc. renowne...
August 1, 2024
Guardant Health: Pioneering Advances in Colorectal Cancer Screening and Liquid Biopsy Technology In an era where the precision oncology landscape is rapidly evolving, Guardant Health, Inc., headquartered in Palo Alto, California, is establishing itself as a formidable player, making significant contributions to improving cancer screening and diagnostics. Recent developments have underscored the company s commitment to enhancing public health outcomes, particularly in the domain of colorectal cancer (CRC) screening and advanced liquid biopsy technology.A hallmark of Guardant Health’s recent efforts is the introduction of the CAN-SCREEN model, a pivotal health outcomes study accepted for publication in the e...
May 31, 2024
Guardant Health: A Leader in Precision Oncology Recognized as One of the TIME100 Most Influential CompaniesPalo Alto, California - Guardant Health, Inc. (NASDAQ:GH), a prominent precision oncology company, has been honored with an inclusion in the prestigious TIME100 Most Influential Companies list. This recognition highlights the company s remarkable impact on the world and its commitment to revolutionizing cancer care. Guardant Health has been chosen out of a pool of global nominations across various sectors, showcasing its exceptional contributions to the field of healthcare.To assemble this remarkable list, TIME solicited nominations from diverse industries and surveyed its extensive network of contribut...
May 9, 2024
PALO ALTO, Calif. In the rapidly evolving world of precision oncology, Guardant Health, Inc. (Nasdaq: GH), a leading industry player, posted impressive Q1 2024 financial results recently. The company reported a revenue of $168.5 million for the first quarter, revealing a 31% increase from the same quarter in the previous year. This significant growth highlights the effectiveness of Guardant Health’s innovative strategies and services in addressing the global challenges related to cancer.The company reported that it had delivered 46,900 tests to clinical customers and an additional 8,450 tests to biopharmaceutical clientele in Q1, marking increases of 20% and 37%, respectively. These numbers highlight the...
May 7, 2024
Guardant Health, the Palo Alto-based company breaking new ground in precision oncology, recently achieved a remarkable milestone of being featured in 500 peer-reviewed publications in esteemed scientific journals. Such an accomplishment highlights the firm s significant impact on cancer research and treatment not just in the United States but also the world over. Guardant Health pioneers the usage of liquid biopsy, an innovative procedure designed to accurately detect and monitor cancer within patients. Through their concentrated efforts, the company has successfully put together one of the industry s most substantial portfolios of liquid biopsy research studies. In precision oncology, personalization formul...
Genedx Holdings Corp operates as a genetic testing company, offering molecular and biochemical testing services for various genetic disorders and diseases. The company generates revenue by providing testing services to medical professionals and institutions around the world, aiding in accurate diagnosis and treatment planning for patients.
Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company's business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.
Mainz Biomed N v operates on a business model focused on the development and commercialization of innovative biomedical solutions. They leverage their expertise in research, development, and manufacturing to create novel biopharmaceutical products with strong market potential. Through strategic partnerships and collaborations, they aim to bring their cutting-edge products to the market, ultimately improving healthcare outcomes.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Sources:
Guardant Health Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Guardant Health Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
